Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,897 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016).
Harano K, Terauchi F, Katsumata N, Takahashi F, Yasuda M, Takakura S, Takano M, Yamamoto Y, Sugiyama T. Harano K, et al. Among authors: takano m. Ann Oncol. 2014 Jan;25(1):251-7. doi: 10.1093/annonc/mdt527. Ann Oncol. 2014. PMID: 24356636 Free article. Clinical Trial.
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Kikuchi Y. Takano M, et al. Int J Clin Oncol. 2007 Aug;12(4):256-60. doi: 10.1007/s10147-007-0670-1. Epub 2007 Aug 20. Int J Clin Oncol. 2007. PMID: 17701003
Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
Takano M, Sugiyama T, Yaegashi N, Sakuma M, Suzuki M, Saga Y, Kuzuya K, Kigawa J, Shimada M, Tsuda H, Moriya T, Yoshizaki A, Kita T, Kikuchi Y. Takano M, et al. Int J Gynecol Cancer. 2008 Sep-Oct;18(5):937-42. doi: 10.1111/j.1525-1438.2007.01158.x. Epub 2007 Dec 13. Int J Gynecol Cancer. 2008. PMID: 18081792
Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
Takakura S, Takano M, Takahashi F, Saito T, Aoki D, Inaba N, Noda K, Sugiyama T, Ochiai K; Japanese Gynecologic Oncology Group. Takakura S, et al. Among authors: takano m. Int J Gynecol Cancer. 2010 Feb;20(2):240-7. doi: 10.1111/igc.0b013e3181cafb47. Int J Gynecol Cancer. 2010. PMID: 20169667 Clinical Trial.
Validation of the histologic grading for ovarian clear cell adenocarcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group.
Yamamoto S, Kasajima A, Takano M, Yaegashi N, Fujiwara H, Kuzuya K, Kigawa J, Tsuda H, Kurachi H, Kikuchi Y, Sugiyama T, Tsuda H, Moriya T. Yamamoto S, et al. Among authors: takano m. Int J Gynecol Pathol. 2011 Mar;30(2):129-38. doi: 10.1097/PGP.0b013e3181f71264. Int J Gynecol Pathol. 2011. PMID: 21293288
1,897 results